Search clinical trials for: ACE-536

Total 3525 results

Celgene

Completed

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Primary Myelofibrosis | Anemia

United States, France, Italy, United Kingdom
M.D. Anderson Cancer Center

Recruiting

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Myelodysplastic Syndromes

China, Japan
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.

Beta-thalassemia

China
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

Myelodysplastic Syndromes

Canada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Beta Thalassemia

Beta-Thalassemia

Greece, Italy
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Myelodysplastic Syndromes

Myelodysplastic Syndromes

Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Anemia

Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia

B-Thalassemia

Italy, Greece
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Recruiting

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Beta-Thalassemia

United States, Turkey, Italy, Thailand, Germany, Greece, China, India, Lebanon
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

Anemia

India
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-536 in Healthy Postmenopausal Women

Anemia

United States
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (BELIEVE)

Beta-Thalassemia | Erythrocyte Transfusion

United States, Israel, Australia, Turkey, Taiwan, Malaysia, United Kingdom, Canada, Thailand, France, Lebanon, Italy, Bulgaria, Greece, Tunisia
Pfizer

Completed

ACTiF- Assessment of Closed Tibial Fractures

Tibial Fractures

United States, Australia, Canada, Spain, Turkey, Croatia, India, Bosnia and Herzegovina, Japan, Russian Federation, South Africa
Bristol-Myers Squibb

Recruiting

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (MAXILUS)

Myelodysplastic Syndromes

Spain, United States, France, Italy, Belgium, Germany, Poland, Czechia, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Recruiting

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Myelodysplastic Syndromes | Anemia | Myeloproliferative Neoplasm

United States
Bristol-Myers Squibb

Recruiting

A Study to Determine the Efficacy and Safety of Luspatercept in Adult and Adolescent Participants With Alpha (α)-Thalassemia

Anemia

Thailand, China, Canada, Turkey, Greece, Taiwan, Italy, Hong Kong
Celgene

Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Beta-thalassemia | Myelodysplastic Syndromes (MDS) | Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

United States, Japan, United Kingdom, Turkey, Greece, France, Australia, Belgium, Bulgaria, Canada, Germany, Israel, Italy, Malaysia, Spain, Sweden, Taiwan, Thailand, Tunisia, Lebanon, China, Netherlands
Groupe Francophone des Myelodysplasies
Celgene

Recruiting

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Myelodysplastic Syndromes | MDS

France
University of Turku
Hoffmann-La Roche

Unknown

Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients

Breast Cancer

Finland
Universidad Francisco de Vitoria
Universidad Rey Juan Carlos

Completed

Physiotherapy for Persistent COVID-19 Disease Using Aerobic Exercise

COVID-19 | Genetic Predisposition to Disease

Spain
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Completed

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia (BEYOND)

Thalassemia

United States, Greece, Italy, Lebanon, Thailand, United Kingdom
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Bristol-Myers Squibb

Recruiting

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (ELEMENT-MDS)

Myelodysplastic Syndromes

Canada, United States, China, Australia, France, Greece, Hungary, Germany, Italy, Czechia, Poland, Mexico, Spain, Brazil, Colombia, India, Argentina, Puerto Rico
Celgene

Terminated

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Beta Thalassemia Intermedia | Beta Thalassemia Major

France, United Kingdom, Italy, Greece
Ace Cells Lab Limited

Unknown

Revitalization of Damaged Skin Due to Chronic Skin Diseases

Psoriasis | Atopic Dermatitis | Chronic Eczema

Serbia, United Kingdom
Seoul National University Hospital
National Evidence-Based Healthcare Collaborating Agency; National Clinical... and other collaborators

Completed

Efficacy of Self-education Program for Advanced Care Planning(RCT) for General Population

Healthy

Korea, Republic of
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral Muscular Dystrophy

United States, Spain, Canada
Megadyne Medical Products Inc.

Unknown

Megadyne Ace Incision/Dissection Study (ACE)

Abdominoplasty | Bilateral Breast Reduction | Bilateral Breast Lift | Bilateral Brachioplasty | Bilateral Lateral Thigh and Buttocks Lift

United States
University of Alabama at Birmingham
ACE Surgical Supply, Inc.

Completed

Evaluation of the ACE Dental Implant (ACE-2005)

Edentulism

United States
Region Zealand

Completed

Reconstruction of the Anterior Cruciate Ligament(ACL-R) in the 30+-Year Old Assessed by Patient Reported Outcome Measures(PRO) Using the Nationwide Danish Knee Ligament Reconstruction Registry

Cruciate Ligament Rupture

Denmark
Assaf-Harofeh Medical Center

Unknown

Anterior Cruciate Ligament (ACL) Reconstruction: Single Bundle Versus Double Bundle

Anterior Cruciate Ligament Tear
Takeda

Completed

A Bioequivalence Study of TAK-536 Pediatric Formulation

Japanese Healthy Adult Males

Japan
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Phase 1 Study of ACE-083 in Healthy Subjects

Musculoskeletal Diseases

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Advanced Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Anemia | Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm

United States
University of Alberta

Completed

Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass (COMPACT)

Coronary Artery Disease

Canada
Cornell University
United States Department of Agriculture (USDA)

Active, not recruiting

Advanced Cooking Education Pilot Study

Adolescent Behavior | Nutrition, Healthy

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

Muscle Loss

Canada
Mikkael Sekeres, MD
Bristol-Myers Squibb; Celgene

Recruiting

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

Myelodysplastic Syndromes

United States
University Hospital, Grenoble

Not yet recruiting

Adverse Childhood Experiences and Infertility : ACESI (ACESI)

Child Abuse | Child Development | Health Behavior | Infertility, Female | Trauma, Psychological
University of New Mexico

Terminated

Adverse Childhood Experiences in Urogynecologic Patients (ACE-UP)

Urinary Incontinence | Pelvic Floor Disorders | Interstitial Cystitis

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

Charcot-Marie-Tooth Disease | Facioscapulohumeral Muscular Dystrophy

United States, Spain, Canada
Boston Scientific Corporation

Completed

The ACE Follow-up Study

Obesity

Netherlands, Argentina, Canada, Israel
Merck Sharp & Dohme LLC

Terminated

Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors

Solid Tumors

United States
Celgene

No longer available

Expanded Access for ACE-011

Myelodysplastic Syndrome

United States
Celgene

Completed

A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis

Anemia | Kidney Failure, Chronic

Belgium, Spain, United Kingdom, Portugal, Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Henry Ford Health System

Terminated

Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure (CATAS-HF)

Heart Failure; With Decompensation

United States

Search clinical trials for: ACE-536

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations